CXCL11 in bronchoalveolar lavage fluid and pulmonary function decline in systemic sclerosis

Clinical and Experimental Rheumatology

Volumn 30, Issue SUPPL.71, 2012, Pages

  Sfriso, Paolo ^a   Cozzi, Franco ^a   Oliviero, Francesca ^a   Caso, Francesco ^a   Cardarelli, Silvia ^a   Facco, Monica ^a   Fittà, Claudio ^a   Del Rosso, Angela ^b   Matucci Cerinic, Marco ^b   Punzi, Leonardo ^a   Agostini, Carlo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Bronchoalveolar lavage fluid; Chemokine CXCL11; Interstitial lung diseases; Systemic sclerosis

Indexed keywords

CXCL11 CHEMOKINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL COUNT; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; FORCED VITAL CAPACITY; HUMAN; LONGITUDINAL STUDY; LUNG ALVEOLUS MACROPHAGE; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; LUNG LAVAGE; LYMPHOCYTE COUNT; MALE; NEUTROPHIL COUNT; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SYSTEMIC SCLEROSIS;

AGED; BIOLOGICAL MARKERS; BRONCHOALVEOLAR LAVAGE FLUID; CASE-CONTROL STUDIES; CHEMOKINE CXCL11; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; ITALY; LOGISTIC MODELS; LONGITUDINAL STUDIES; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84867374217     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. LEE P, LANGEVITZ P, ALDERDICE CA et al.: Mortality in systemic sclerosis (scleroderma). Q J Med 1992; 82: 139-48.
2. MORGAN C, KNIGHT C, LUNT M, BLACK CM, SILMAN AJ: Predictors of end stage lung disease in a cohort of patients with scleroderma. Ann Rheum Dis 2003; 62: 146-50.
3. KIM DS, YOO B, LEE JS et al.: The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19: 121-7.
4. BOUROS D, WELLS AU, NICHOLSON AG et al.: Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J RespirCrit Care Med 2002; 165: 1581-6.
5. STEEN VD, MEDSGER TA JR.: Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43: 2437-44.
6. TYNDALL AJ, BANNERT B, VONK M et al.: Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809-15
7. WHITE B, MOORE WC, WIGLEY FM, XIAO HQ, WISE RA: Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000; 132: 947-954.
8. TASHKIN DP, ELASHOFF R, CLEMENTS PJ et al.: Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655-66.
9. HOYLES RK, ELLIS RW, WELLSBURY J et al.: A multicenter, prospective, randomized, double-blind, placebo-controlledtrialofcorticosteroidsandintravenouscyclophosphamidefollowedby oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006; 54: 3962-70.
10. COLACI M, SEBASTIANI M, GIUGGIOLI D et al.: Bronchoalveolar lavage and response to cyclophosphamide in scleroderma alveolitis. Scand J Rheumatol 2010; 39: 155-96.
11. BAJWA EK, AYAS NT, SCHULZER M, MAK E, RYU JH, MALHOTRA A: Interferon-gamma1b therapy in idiopathic pulmonary fibrosis: a metaanalysis. Chest 2005; 128: 203-6.
12. STRIETER RM, STARKO KM, ENELOW RI, NOTH I, VALENTINE VG: Idiopathic Pulmonary Fibrosis Biomarkers Study Group. Effects of interferon-gamma 1b on biomarker expression in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2004; 170: 133-40.
13. BURDICK MD, MURRAY LA, KEANE MP et al.: CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling. Am J RespirCrit Care Med 2005; 171: 261-8.
14. SUBCOMMITTEE FOR SCLERODERMA CRITERIA OF THE AMERICAN RHEUMATISM ASSOCIATION DIAGNOSTIC AND THERAPEUTIC CRITERIA COMMITTEE: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
15. LEROY EC, BLACK C, FLEISCHMAJER R et al.: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5.
16. WARRICK JH, BHALLA M, SCHABEL SI, SILVER RM: High resolution computed tomography in early scleroderma lung disease. J Rheumatol 1991; 18: 1520-8.
17. COSTABEL U, DANEL C, HASLAM P et al.: Technical recommendations and guidelines for bronchoalveolar lavage (BAL). Report of the European Society of Pneumology Task Group on BAL. EurRespir J 1989; 2: 561-85.
18. GREENWALD GI, TASHKIN DP, GONG H et al.: Longitudinal changes in lung function and respiratory symptoms in progressive systemic sclerosis. Prospective study. Am J Med 1987; 83: 83-92.
19. WITT C, BORGES AC, JOHN M, FIETZE I, BAUMANN G, KRAUSE A: Pulmonary involvement in diffuse cutaneous systemic sclerosis: bronchoalveolar fluid granulocytosis predicts progression of fibrosing alveolitis. Ann Rheum Dis 1999; 58: 635-40.
20. GOH NS, VEERARAGHAVAN S, DESAI SR et al.: Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum 2007; 56: 2005-12.
21. AGOSTINI C, GURRIERI C: Chemokine/ Citokine cocktail in idiopathic pulmonary fibrosis. Proc Am Thorac Soc 2006; 3: 357-63.
22. SCHMIDT K, MARTINEZ-GAMBOA L, MEIER S et al.: Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients. Arthritis Res Ther 2009; 11: R111.
23. LUKACS NW, HOGABOAM C, CHENSUE SW, BLEASE K, KUNKEL SL: Type 1/type 2 cytokine paradigm and the progression of pulmonary fibrosis. Chest 2001; 120: 5S-8S.